Transcatheter Aortic Valve Implantation - Yesterday, Today and Tomorrow

Area of Science:

• Cardiovascular Medicine
• Interventional Cardiology

Background:

• Transcatheter aortic valve implantation (TAVI) emerged in 2002 as a less invasive alternative to conventional surgical valve replacement.
• It addresses a critical need for high-risk patients ineligible for traditional surgery, offering improved survival and morbidity benefits over medical therapy.

Observation:

• Over 200,000 TAVI devices have been implanted globally, with rapid technological and procedural evolution over 13 years.
• Clinical approval has expanded to over 50 countries, reflecting TAVI's established efficacy and safety in select patient groups.
• The rapid pace of innovation presents challenges, potentially causing research and regulatory processes to lag behind clinical adoption.

Findings:

• TAVI demonstrates at least equivalent outcomes to surgical valve replacement in specific patient cohorts.
• Evidence supports significant morbidity and mortality advantages of TAVI compared to medical management.
• The evolution impacts all TAVI stages, from patient assessment to post-procedural care.

Implications:

• The rapid evolution of TAVI necessitates continuous evaluation of its long-term impact and comparative effectiveness.
• Ongoing research is crucial to validate new technologies and guide regulatory approvals.
• Understanding TAVI's trajectory is key for optimizing patient selection and future therapeutic strategies.